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Abstract
Background: Cathepsin B and L (CATB, CATL), urokinase-type plasminogen activator (uPA) and
its inhibitor PAI-1 play an important role in colorectal cancer invasion. The tumor marker utility
and prognostic relevance of these proteases have not been evaluated in the same experimental
setting and compared with that of CEA and CA-19-9.
Methods: Protease, CEA and CA 19-9 serum or plasma levels were determined in 56 patients with
colorectal cancer, 25 patients with ulcerative colitis, 26 patients with colorectal adenomas and 35
tumor-free control patients. Protease, CEA, CA 19-9 levels have been determined by ELISA and
electrochemiluminescence immunoassay, respectively; their sensitivity, specificity, diagnostic
accuracy have been calculated and correlated with clinicopathological staging.
Results: The protease antigen levels were significantly higher in colorectal cancer compared with
other groups. Sensitivity of PAI-1 (94%), CATB (82%), uPA (69%), CATL (41%) were higher than
those of CEA or CA 19-9 (30% and 18%, respectively). PAI-1, CATB and uPA demonstrated a
better accuracy than CEA or CA 19-9. A combination of PAI-1 with CATB or uPA exhibited the
highest sensitivity value (98%). High CATB, PAI-1, CEA and CA 19-9 levels correlated with
advanced Dukes stages. CATB (P = 0.0004), CATL (P = 0.02), PAI-1 (P = 0.01) and CA 19-9 (P =
0.004) had a significant prognostic impact. PAI-1 (P = 0.001), CATB (P = 0.04) and CA 19-9 (P =
0.02) proved as independent prognostic variables.
Conclusion:  At the time of clinical detection proteases are more sensitive indicators for
colorectal cancer than the commonly used tumor markers. Determinations of CATB, CATL and
PAI-1 have a major prognostic impact in patients with colorectal cancer.
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Background
Colorectal cancer (CRC) is the most common gastrointes-
tinal cancer in the Western world and it is an important
cause of cancer-related death, tumor stage being generally
considered the strongest prognostic factor in CRC [1,2].
Great effort has been dedicated to the search of sensitive
and specific markers of the disease and up to now, carci-
noembryonic antigen (CEA) and the gastrointestinal can-
cer-associated carbohydrate antigen (CA 19-9) are the
most widely applied markers in gastrointestinal malig-
nancies, e.g., CRC or pancreatic cancer [3-7].
Prediction of survival is another feature requested for
tumor markers and elevated levels of both CEA and CA
19-9 have also been reported to be associated with poor
prognosis in CRC [8-12]. However, because of their low
sensitivity, CEA and CA 19-9 seem to be unacceptable
both for screening for CRC [3,13,14]. Therefore, there is a
need for a search of additional tumor-related antigens, eli-
gible as tumor markers in gastrointestinal malignancies.
Tumor cells have been shown to produce and release sev-
eral proteolytic enzymes, which are thought to be
involved in tumor invasion and metastasis [15]. For
instance, it has been observed that cathepsin B (CATB)
and cathepsin L (CATL), which are cysteine proteases, the
serine protease urokinase-type plasminogen activator
(uPA) and its inhibitor type-1 (PAI-1) play a crucial role
in this process through the destruction of various ele-
ments of the cell-surrounding extracellular matrix [16-
21].
Several human solid tumors have been reported to have
increased levels of proteolytic enzymes in cancer tissue,
strongly suggesting that proteases may be important in
tumor invasion and metastasis. With respect to the gas-
trointestinal tract, we have previously demonstrated that
proteolytic enzymes are widely distributed in gastrointes-
tinal tissues, being implicated in processes of gastrointes-
tinal tissue remodelling and angiogenesis [22], may have
a role not only in the process of esophageal [23], gastric
[24,25] or colorectal cancer invasion [26], but also in the
progression of gastrointestinal precancerous changes into
cancer [27].
Cathepsins and components of the plasminogen activator
and inhibitor system have been demonstrated in various
malignant tissues, e.g., breast cancer [28-30], lung cancer
[31,32], head and neck cancer [33], ovarian cancer [34],
gastric cancer [35-38] or CRC [39-45] and might therefore
be useful as a diagnostic tool.
With respect to the gastrointestinal tract, several studies,
along with our own, have pointed to the prognostic value
of proteases for survival, for instance, in gastric cancer
[24,25,38,46,47] and CRC [26,40,43,48-50].
A number of studies have demonstrated an elevation of
serum or plasma protease levels in patients suffering from
CRC [51-55], however, to our knowledge, the tumor
marker utility of CATB, CATL, uPA and PAI-1 has not been
evaluated in the same experimental setting, and compared
with that of the most commonly used gastrointestinal
tumor markers, such as CEA and CA-19-9.
Therefore, the objective of the present study was to assess
the possible clinical relevance of serum CATB, CATL and
plasma uPA, PAI-1 antigen levels in the same CRC
patients, compare them with the already established
serum markers CEA and CA 19-9, and to evaluate any cor-
relation between these parameters and clinicopathologi-
cal and prognostic staging of CRC.
Methods
The study comprised 56 patients with CRC, who under-
went colorectal resection, 29 males and 27 females, mean
age 65.4 ± 12.8 years (range 39–86 years) and 35 tumor-
free control patients (controls) with negative gastroscopy
and colonoscopy, 12 males and 23 females, mean age
46.3 ± 13.4 years (range 24–85 years). For further compar-
ison we also investigated 25 patients with ulcerative colitis
(UC) without dysplasia as confirmed by colonoscopy and
biopsy, 11 males and 14 females, mean age: 31.7 ± 6.6
years (range 22–48 years), and 26 patients with colorectal
adenoma confirmed by histology after endoscopic
polypectomy (samples consisted of 16 tubular adenomas
with low grade dysplasia and 10 tubulovillous adenomas
with high grade dysplasia), 17 males and 9 females, mean
age 57.8 ± 6.9 years (range 47–72 years). Informed con-
sent was obtained from all patients. The study was
approved by the Ethical Committee of Semmelweis Uni-
versity Budapest and Padova University.
In all instances, this was a first diagnosis of CRC, and no
recurrences were taken into consideration. Patients who
were undergoing chemotherapy, radiotherapy, or any
other adjuvant therapy for CRC, or were expected to
undergo such therapies within the study period were not
included.
Clinical data of the patients and histology of tumors were
registered accurately. Pathologic staging was obtained for
the presence (n= 37) or absence (n = 19) of lymph node
and/or distant metastases, and for differentiation (well
differentiated, G1 (n = 17); moderately differentiated, G2
(n = 30); or poorly differentiated, G3 (n = 9). Finally, the
tumors were also subgrouped according to their tumor
location (colon cancer, n = 38; rectal cancer, n = 18). The
tumors were histologically classified according to DukesBMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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classification, as modified by Turnbull et al. [56]. Dukes
stage A tumors were confined to the bowel wall (n = 7);
Dukes stage B tumors have spread beyond the wall with-
out involving lymph nodes (n = 12); Dukes stage C were
associated with regional lymph node metastases (n = 23);
and finally, Dukes stage D tumors were associated with
distant metastases (n = 14).
Blood collection
Serum and plasma samples were collected from patients
with CRC at the time of clinical tumor detection. Blood
samples were collected from resting patients after a 12 h
fasting between 8:00 and 10:00 a.m. to avoid possible
influences of circadian variations on the fibrinolytic sys-
tem. Blood was drawn from a cubital vein with minimal
venous occlusion directly into plastic tubes prepared with
sodium citrate (0.1 M final concentration) as an anticoag-
ulant to avoid platelet activation and platelet contamina-
tion. Plasma was obtained by centrifugation at 3000 × g
for 15 min at 4°C, harvested and snap-frozen. The sam-
ples were stored at -70°C until analysis.
Determination of established tumor markers and 
proteases
Serum CEA (carcinoembryonic antigen electrochemilu-
minescence immunoassay "ECLIA", Cobas®, Roche, Diag-
nostics, Mannheim, Germany; cut-off limit, 4.0 ng/ml)
and serum CA 19-9 (carbohydrate electrochemilumines-
cence immunoassay "ECLIA", Cobas®, Roche, Diagnos-
tics, Mannheim, Germany; cut-off limit, 37.0 ng/ml) were
determined by commercially available test kits and mon-
oclonal antibodies. Cut-off limits were taken as recom-
mended by the manufacturers.
The assays for CATB, CATL, uPA and PAI-1 have been pub-
lished elsewhere [22,26]. Antigen levels were measured by
using the enzyme-linked immunoassay (ELISA) method
as follows: briefly, cathepsin immunoassay is a solid-
phase ELISA based on the sandwich principle (BiAss,
Diesen, Germany). Absolute quantities of CATB and CATL
antigens in the serum samples were calculated from a 7-
point standard curve of CATB and CATL (0–250 ng/ml).
The lowest detectable concentrations were estimated at ≅
1 ng/ml.
The uPA antigen was determined by using the TintElize
uPA-ELISA (Biopool, Umea, Sweden). The amount of uPA
antigen in the plasma samples was calculated from a 6-
point standard curve of uPA (0–4 ng/ml). The detection
limit was ≅ 0.1 ng/ml for uPA.
PAI-1 antigen quantification was performed by using the
Asserachrom PAI-1 ELISA (Diagnostica Stago, Asniéres-
sur-Seine, France). Absolute quantities of PAI-1 antigen in
the plasma samples were calculated from a 7-point stand-
ard curve of PAI-1 (0–250 ng/ml). The detection limit was
≅ 0.5 ng/ml for PAI-1.
Statistics
Due to the high standard deviations of some of the series,
results were expressed as median levels and, after evalua-
tion by using the Kolmogorov-Smirnov test, differences
between groups were tested statistically by using the
Mann-Whitney U test and the Kruskall-Wallis analysis of
variance, where applicable. Spearman rank correlation
test was performed to evaluate the correlation between
CATB, CATL, uPA, PAI-1, CEA and CA 19-9. Differences
were considered significant with P < 0.05. The receiver
operating characteristics (ROC) curves were used to deter-
mine the optimal cut-off values (with the Youden J test for
overall accuracy). The areas under curve (AUCs) for all
investigated biomarkers were determined according to
ROC curves. The discriminative power of each biomarker
for the diagnostic accuracy was tested by Fisher's exact test.
The association of proteases and CEA, CA 19-9 and sur-
vival was tested using their median values in the group of
CRC. The Kaplan-Meier method was used to estimate sur-
vival probabilities, and the log-rank test was used to test
equality of strata. Group-oriented curves for survival were
calculated according to the Kaplan-Meier method for
CATB, CATL, uPA and PAI-1 antigen levels; CEA and CA
19-9; Dukes classification; grade; tumor location; age and
gender. The Cox proportional hazards model was applied
for multivariate analysis. Variables were included in the
multivariate analysis only if the P value was less than 0.05
in the univariate analysis. The SAS software package (SAS
Institute, Cary, North Carolina) was used to perform sta-
tistical analyses.
Results
Serum and plasma concentrations for CATB, CATL, uPA,
PAI-1, CEA and CA 19-9 in patients with CRC, UC, color-
ectal adenoma and controls, expressed in ng/ml, are
shown in Table 1. Significantly higher CATB, CATL, uPA
and PAI-1 antigen concentrations were observed in CRC
patients compared with controls, patients with UC or
colorectal adenomas. No statistically significant differ-
ences were seen with respect to CEA and CA 19-9 levels.
Antigen levels of CATB, CATL and PAI-1 were significantly
higher in blood samples from patients with colorectal
adenomas than from controls. CATB, CATL, uPA and PAI-
1 showed a trend towards increase in patients with UC
compared with controls, but the differences were statisti-
cally not significant (Table 1).
With respect to Dukes classification, CATB, PAI-1, CEA
and CA 19-9 showed the highest antigen concentrations
in patients with Dukes stage D tumors (Table 2).BMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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Antigen levels of CATB, CATL, uPA, PAI-1 and CEA, CA
19-9 levels showed a trend toward higher levels in patients
with colon cancer compared to patients with rectal cancer,
but the differences were not statistically significant (data
not shown). No statistically significant changes were
observed in association with tumor grade, age or gender
(data not shown).
The receiver operating characteristics (ROC) curves were
used to determine the optimal cut-off values (with the
Youden J test for overall accuracy). The optimal cut-off
value for CATB was 4.60 ng/ml (Youden J = 0.68), the cut-
off for CATL was placed at 1.12 ng/ml (Youden J = 0.25).
The optimal selected cut-off values for uPA and PAI-1
were 0.21 ng/ml (Youden J  = 0.53) and 18.90 ng/ml
(Youden J = 0.75), respectively. Cut-off limits for CEA (4.0
ng/ml) and CA 19-9 (37.0 ng/ml) were taken as recom-
mended by the manufacturers.
Sensitivity was calculated as the percentage of individuals
in the tumor groups (test-positive tumor patients) who
showed concentrations of tumor markers above the
respective cut-off limits. Specificity was calculated as the
percentage of test-negative, non-tumor individuals, which
could be either healthy individuals (controls), those with
UC or patients with colorectal adenomas.
Table 1: Proteolytic enzymes, CEA and CA 19-9 in patients with colorectal cancer, ulcerative colitis, adenoma and controls.
CATB CATL uPA PAI-1 CEA CA 19-9
Colorectal cancer (n = 56) 8.75*§
(2.4–39.3)
1.10*§
(1.0–35.3)
0.29*§
(0.1–0.79)
52.45*§
(13.5–138.6)
2.40
(0.4–235.0)
9.15
(1.0–540.0)
Ulcerative colitis
(n = 25)
4.37
(2.8–7.2)
1.10
(1.0–1.7)
0.20
(0.18–0.23)
12.60
(8.8–17.6)
3.15
(0.8–11.5)
9.00
(4.5–32.0)
Colorectal adenoma (n = 26) 4.45#
(4.2–10.3)
1.25#
(1.0–6.5)
0.20
(0.16–0.53)
14.05#
(10.5–65.5)
3.55
(0.7–5.7)
10.27
(3.7–41.0)
Controls (n = 35) 3.80
(1.4–5.8)
1.00
(1.0–2.1)
0.19
(0.16–0.27)
10.70
(1.87–23.8)
2.90
(0.8–18.9)
8.90
(1.27–47.4)
Kruskall-Wallis analysis of variance (P value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = NS P = NS
Cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 levels in patients with 
colorectal cancer (n = 56), ulcerative colitis (n = 25), colorectal adenoma (n = 26) and controls (n = 35) expressed in ng/ml (median values and 
range)
Statistics:
* Colorectal cancer: P < 0.001 vs Controls
§ Colorectal cancer: P < 0.05 vs Ulcerative colitis and Colorectal adenoma
# Colorectal adenoma: P < 0.001 vs Controls
Abbreviations: CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; 
CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; NS: not significant
Table 2: Proteolytic enzymes, CEA and CA 19-9 in correlation with Dukes classification.
Stage CATB CATL uPA PAI-1 CEA CA 19-9
DUKES A (n = 7) 4.50
(2.4–37.3)
1.10
(1.0–35.3)
0.30
(0.2–0.62)
32.81
(17.2–66.7)
3.00
(0.6–3.4)
6.80
(3.0–11.5)
DUKES B (n = 12) 6.75
(3.2–23.8)
1.00
(1.0–12.3)
0.29
(0.1–0.79)
39.09
(13.5–108.1)
2.00
(0.6–21.1)
7.65
(1.0–35.0)
DUKES C (n = 23) 8.60
(3.6–35.7)
1.10
(1.0–34.1)
0.26
(0.1–0.79)
52.54
(13.8–126.4)
2.20
(0.4–235.0)
9.20
(1.0–78.6)
DUKES D (n = 14) 24.25*§
(9.2–39.3)
4.55
(1.0–35.2)
0.29
(0.12–0.42)
82.03**
(38.7–138.6)
8.30#
(1.9–74.6)
35.85**
(4.6–540.0)
Kruskall-Wallis analysis of variance (P value) P = 0.0002 P = NS P = NS P = 0.01 P = 0.003 P = 0.001
Cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 levels in association with 
Dukes classification of colorectal cancer expressed in ng/ml (median values and range)
Statistics:
*P < 0.01, Dukes D vs Dukes A and B
§P < 0.05, Dukes D vs Dukes C
**P < 0.05, Dukes D vs Dukes A, B and C
#P < 0.01, Dukes D vs Dukes A, B and C
Abbreviations: DUKES A: Dukes stage A; DUKES B: Dukes stage B; DUKES C: Dukes stage C; DUKES D: Dukes stage D; CATB: cathepsin B; CATL: 
cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: 
carbohydrate antigen 19-9; NS: not significantBMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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When proteases, CEA and CA 19-9 were used as single
markers, considering the above mentioned optimal cut-
off values, sensitivity of PAI-1 (94%), CATB (82%), uPA
(69%) and CATL (41%) were more indicative for CRC
than CEA or CA 19-9 (30% and 18%, respectively). Spe-
cificity of CATB (88%) and PAI-1 (84%) was in the same
range than that of the established markers (CA 19-9: 93%,
CEA: 89%) (Table 3).
PPV (probability of detection a CRC by a positive test)
and NPV values (probability of exclusion of a CRC suspi-
cion by a negative test) are post-test probabilities and thus
strongly dependent on the pre-test probability (positive
prevalence) reflecting the percentage of tumor patients in
all patient groups investigated, i.e. 56/142 = 39%, and
negative prevalence reflecting the percentage of non-
tumor individuals in all patient groups investigated, i.e.
86/142 = 61%. The comparison of positive prevalence
with PPV and negative prevalence with NPV allows to
judge the utility of PPV and NPV values in relation to a
probability by chance, i.e. they should differ from the
prevalence by at least 20%. According to this, the PPV val-
ues were of relevance for CATB, uPA, PAI-1, CEA and CA
19-9, and less for CATL; inversely, the NPV values were of
relevance for CATB, PAI-1, uPA, but not at all for CATL,
CEA and CA 19-9 (Table 3).
PAI-1, CATB and uPA demonstrated a better diagnostic
accuracy than CEA, CATL or CA 19-9, PAI-1 showed the
highest accuracy (Table 3).
The clinical relevance of the different markers is demon-
strated by ROC curves. The ROC curves of PAI-1 and CATB
were located closer to the theoretical 100% sensitivity and
specificity values than the ROC curves of other investi-
gated markers (Figure 1).
Table 4 summarizes the areas under curve (AUCs) for all
investigated biomarkers. Again, PAI-1 and CATB demon-
strated the highest accuracy and the best discriminative
power.
Sensitivity and specificity values during multiparametric
tumor marker analysis are given in Table 5. When two
markers were determined in identical blood samples,
combined sensitivity values disclosed the superiority of
the combination of PAI-1 together with CATB or uPA
(both markers correctly test-positive for tumor patients in
78% and 64%, respectively; one of two markers correctly
test-positive in the tumor group in 98%) as compared to
the combinations of all other markers, including pro-
teases with CEA or CA 19-9, or CEA with CA 19-9. The
sensitivity of CEA or CA 19-9 in combination with a pro-
tease antigen level was more indicative for CRC than CEA
or CA 19-9 alone (when one of two markers was correctly
test-positive). The combined use of three markers (one
protease in combination with CEA and CA 19-9) did not
lead to a further increase in sensitivity.
The specificity of CEA or CA 19-9 in combination with a
protease antigen level or the combination of CEA with CA
19-9 was more indicative for correctly negative patients
than CEA or CA 19-9 alone (when one of two markers was
correctly test-negative for non-tumor patients). When two
protease levels were considered, combined specificity val-
ues (one of two markers correctly test-negative for non-
tumor group) were also higher than specificity of CATB,
CATL, uPA or PAI-1 as a single marker. The combined use
of three markers (one protease in combination with CEA
and CA 19-9) did not lead to a further increase in specifi-
city (Table 5).
Table 3: Diagnostic accuracy of proteolytic enzymes, CEA and CA 19-9 in colorectal cancer.
CATB CATL uPA PAI-1 CEA CA 19-9
Cut-off (4.60) (1.12) (0.21) (18.90) (4.0) (37.0)
Sensitivity ( % ) 8 24 16 9 9 43 0 1 8
Specificity ( % ) 8 88 08 2 8 48 9 9 3
PPV ( % ) 8 25 87 2 7 96 5 6 2
PPV-Positive Prevalence ( % ) 4 31 93 3 4 02 6 2 3
NPV ( % ) 8 86 88 0 9 66 6 6 3
NPV-Negative Prevalence ( % ) 2 771 93 552
Accuracy ( % ) 8 66 57 7 8 86 6 6 3
Fisher's Exact Test P < 0.0001 P = 0.008 P < 0.0001 P < 0.0001 P = 0.004 P = 0.06
Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of cathepsin B, cathepsin L, urokinase-type plasminogen 
activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
Abbreviations: PPV: Positive predictive value; NPV: Negative predictive value; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type 
plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; Cut-off: 
cut-off values expressed in ng/ml; Positive Prevalence: the percentage of tumor patients in all patient groups investigated, i.e. 56/142 = 39%; 
Negative Prevalence: the percentage of non-tumor individuals in all patient groups investigated, i.e. 86/142 = 61%; PPV-Positive Prevalence: the 
difference between PPV and positive prevalence; NPV-Negative Prevalence: the difference between NPV and negative prevalenceBMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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Table 6 demonstrates associations between proteases and
CEA/CA 19-9, determined in identical blood samples
obtained from CRC patients. When correlation analysis
was assessed between proteases, CATB significantly corre-
lated with CATL, uPA and PAI-1. Significant correlations
were also found between the antigen levels of PAI-1 and
CATL, and finally PAI-1 and uPA. CEA and CA 19-9 also
significantly correlated in the group of CRC. When Spear-
man rank correlation test was performed in CRC between
CEA, CA 19-9 and proteases, both CEA and CA 19-9 sig-
nificantly correlated with CATB and PAI-1.
The CRC patients were enrolled in a follow-up protocol.
The follow-up ended at the event of death or, when the
patient was still alive, at the last follow-up date. Patients
were followed either directly or through their attending
physicians. Thirty-five patients (62.5%) died of tumor
recurrence. Their median survival was 32 months (95%
CL, 23–38; range, 7–78 months). At the end of follow-up
period, 21 patients (37.5%) were still alive; their median
follow-up was 86 months (95% CL, 85–91; range 76–96
months). The median survival time calculated for all
patients was 45 months (95% CL, 43–61; range 7–96
months). The median survival for the subgroup of
patients who underwent curative resection (Dukes A-C)
was 77 months (95%CL, 56–73, range 7–96 months),
whereas it was 14 months in the remaining group of
patients with Dukes D tumors (95%CL, 11–19; range,
8–36 months; P < 0.001).
No statistically significant difference was observed in asso-
ciation with tumor location (median survival period for
patients with colon cancer and rectal cancer: 43 months,
Table 4: The areas under curve for proteolytic enzymes, CEA 
and CA 19-9 according to ROC curves.
Variable AUC Lower limit Upper limit
PAI-1 0.9385 0.9025 0.9744
CATB 0.8665 0.7934 0.9397
uPA 0.7143 0.6091 0.8196
CATL 0.6173 0.5158 0.7188
CA 19-9 0.4990 0.3937 0.6043
CEA 0.4748 0.3690 0.5807
Determination of areas under curve for cathepsin B, cathepsin L, 
urokinase-type plasminogen activator, plasminogen activator inhibitor 
type-1, CEA and CA 19-9 according to ROC curves allowing to 
evaluate their accuracy and different discriminative power
Abbreviations: AUC: area under curve; CATB: cathepsin B; CATL: 
cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: 
plasminogen activator inhibitor type-1; CEA: carcinoembryonic 
antigen; CA 19-9: carbohydrate antigen 19-9; ROC: receiver 
operating characteristics
ROC curves for proteolytic enzymes, CEA and CA 19-9 in patients with colorectal cancer Figure 1
ROC curves for proteolytic enzymes, CEA and CA 19-9 in patients with colorectal cancer. The clinical relevance 
of cathepsin B (CATB), cathepsin L (CATL), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor type-
1 (PAI-1), CEA and CA 19-9 was compared by establishing ROC curves. The ROC curves of PAI-1 and CATB were located 
closer to the theoretical 100% sensitivity and specificity values than the ROC curves of other investigated markers.BMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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95%CL, 40–62; range, 8–96 months, and 55 months,
95%CL, 37–70, range, 7–94 months, respectively).
The association of proteolytic enzymes and CEA, CEA-19
and survival was tested using their median values in the
group of CRC (CATB: 8.75 ng/ml; CATL: 1.1 ng/ml; uPA:
0.29 ng/ml; PAI-1: 52.45 ng/ml; CEA: 2.40 ng/ml; CA 19-
9: 9.15 ng/ml).
In univariate survival analysis, CATB antigen levels (P =
0.0004) (Figure 2A), CATL antigen levels (P = 0.02) (Fig-
ure 2B), PAI-1 antigen levels (P = 0.01) (Figure 2C), CA
19-9 (P = 0.004), and Dukes classification (P < 0.0001)
were significantly correlated with survival. No significant
correlation was observed with respect to uPA antigen lev-
els, CEA, tumor grade, tumor location, age and gender. To
determine the independent value of these prognostic fac-
tors, multivariate analysis was performed. Variables were
included in the multivariate analysis only if the P value
was less than 0.05 in the univariate analysis. In the multi-
variate statistical analysis all parameters – including
Dukes classification, PAI-1, CATB, CATL and CA 19-9 –
were tested in one model. According to this, significant
independent prognostic information was obtained from
Dukes classification (P = 0.004), PAI-1 (P = 0.001), CATB
(P = 0.04) and CA 19-9 (P = 0.02), but not from CATL.
Analysed as continuous variables in the Cox model, PAI-1
(HR 2.22, P = 0.001), CATB (HR 2.09, P = 0.04) and CA
19-9 (HR 1.98, P = 0.02) were found to be Dukes-inde-
pendent prognostic factors (Table 7).
Discussion
Among several tumor markers, that are suggested to corre-
late with the presence and prognosis of CRC, CEA and CA
Table 5: Multiparametric tumor marker analysis in colorectal cancer.
Colorectal cancer
Sensitivity Specificity
Two markers Both positive Either positive Both negative Either negative
PAI-1 + CATB 78% 98% 73% 98%
PAI-1 + uPA 64% 98% 67% 98%
PAI-1 + CATL 39% 96% 67% 96%
CATB + uPA 55% 95% 79% 87%
CATB + CATL 41% 84% 75% 94%
CATL + uPA 30% 80% 72% 90%
PAI-1 + CEA 30% 96% 73% 98%
CATB + CEA 28% 84% 83% 95%
uPA + CEA 20% 80% 76% 95%
CATL + CEA 20% 52% 75% 94%
PAI-1 + CA 19-9 18% 96% 77% 98%
CATB + CA 19-9 16% 84% 86% 97%
uPA + CA 19-9 14% 73% 80% 95%
CATL + CA 19-9 11% 48% 78% 95%
CEA + CA 19-9 16% 32% 86% 97%
Three markers All positive Either positive All negative Either negative
PAI-1 +CEA +CA 19-9 16% 96% 71% 98%
CATB +CEA +CA 19-9 14% 84% 80% 97%
uPA +CEA +CA 19-9 12% 80% 74% 97%
CATL +CEA +CA 19-9 9% 52% 74% 97%
Sensitivity and specificity values of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and 
CA 19-9 during multiparametric tumor marker analysis in colorectal cancer (n = 56)
CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: 
carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9;
Both: both markers correctly positive or negative; All: all three markers correctly positive or negative; Either: one of two/or three markers 
correctly positive or negativeBMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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19-9 are the most widely accepted [3-7]. However, the
rather low sensitivity of serum CEA or CA 19-9, their
secretion rates from individual tumors and nonspecific
elevations reduce their tumor marker utility and indicate
the need for additional more reliable markers for CRC.
Proteolytic mechanisms, such as those that depend on
cysteine (CATB, CATL) and serine proteases (uPA, PAI-1)
are recognized as crucial factors in tumor invasion and
metastasis. Cysteine proteases (CATB, CATL) play an
important role in this process through the destruction of
various elements of cell-surrounding extracellular matrix,
whereas uPA appears to promote invasion through a plas-
min-mediated degradation of extracellular matrix pro-
teins. Active uPA catalyses the conversion from
plasminogen to plasmin, that is a potent activator of sev-
eral metalloproteinase proenzymes, such as prostrome-
lysin, procollagenase, and progelatinase. Beyond its direct
proteolytic capacity, CATB has been shown also to activate
the pro-urokinase-type plasminogen activator (pro-uPA).
PAI-1 under normal physiologic conditions inhibits uPA
by forming a covalent enzyme-inhibitor complex. How-
ever, the exact role of PAI-1 in tumor biology is not well
established. It has been suggested that PAI-1 may repre-
sent a specific protein of transformed malignant tissue
and it has also been claimed that PAI-1 may serve to pro-
tect cancer tissue against the proteolytic degradation trig-
gered by the tumor on surrounding normal tissue.
Furthermore, the inhibitor has a role in angiogenesis,
Table 6: Correlation analysis of proteolytic enzymes, CEA and 
CA 19-9 in colorectal cancer.
Colorectal cancer
P value (correlation coefficient)
CATB/CATL P = 0.0001 (rS = 0.67)
CATB/uPA P = 0.03 (rS = 0.28)
CATB/PAI-1 P = 0.04 (rS = 0.27)
CATL/uPA P = 0.11 (rS = 0.21)
PAI-1/CATL P = 0.03 (rS = 0.27)
PAI-1/uPA P = 0.001 (rS = 0.41)
CEA/CA 19-9 P = 0.0003 (rS = 0.46)
CEA/CATB P = 0.002 (rS = 0.40)
CEA/CATL P = 0.06 (rS = 0.25)
CEA/uPA P = 0.70 (rS = 0.05)
CEA/PAI-1 P = 0.002 (rS = 0.40)
CA 19-9/CATB P = 0.005 (rS = 0.36)
CA 19-9/CATL P = 0.33 (rS = 0.13)
CA 19-9/uPA P = 0.46 (rS = 0.10)
CA 19-9/PAI-1 P = 0.005 (rS = 0.36)
Correlation of cathepsin B, cathepsin L, urokinase-type plasminogen 
activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in 
patients with colorectal cancer (n = 56)
Abbreviations: CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-
type plasminogen activator, PAI-1: plasminogen activator inhibitor 
type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate 
antigen 19-9; rS: Spearman rank correlation coefficient
Table 7: Univariate and multivariate analysis of survival in patients with colorectal cancer.
Univariate analysis Multivariate analysis
Log-Rank Test Cox Proportional Hazards Model
Variable P value P value HR (95% CL)
Dukes < 0.0001 0.004 1.88 (1.22–2.89)
PAI-1 0.012 0.001 2.22 (1.21–4.06)
CATB 0.0004 0.042 2.09 (1.02–4.26)
CATL 0.021 0.639 1.17 (0.60–2.29)
CA 19-9 0.004 0.024 1.98 (1.09–3.58)
uPA 0.369
CEA 0.159
Grade 0.420
Location 0.566
Age 0.247
Gender 0.122
Univariate analysis including Dukes classification, cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor 
type-1, CEA, CA 19-9, tumor grade, tumor location, age, and gender. Variables were included in the multivariate analysis only if the P value was less 
than 0.05 in the univariate analysis. In the multivariate statistical analysis all parameters -including Dukes classification, PAI-1, CATB, CATL and CA 
19-9 – were tested in one model.
Abbreviations: Dukes: Dukes classification; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen 
activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; Grade: tumor grade (differentiation); Location: 
tumor location; HR: Hazard ratio; 95% CL: 95% Hazard ratio confidence limitsBMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
Page 9 of 12
(page number not for citation purposes)
which has an important part to play in tumor spread [15-
21].
Several studies have suggested the potential impact of pro-
teases as tumor markers in CRC [51-55]. Given the lack in
the literature for a comparison of the tumor marker utility
and possible prognostic relevance of cathepsins (CATB,
CATL) and the uPA/PAI-1 system in the same experimen-
tal setting, in the current study, we surveyed the behavior
of CATB, CATL, uPA, PAI-1 in CRC and compared with
commonly used gastrointestinal tumor markers CEA and
CA 19-9, and then evaluated any correlation between
these parameters and the clinicopathological staging of
CRC.
In our study, antigen levels of proteases were measured by
using ELISA method. Most ELISAs used to measure uPA
and PAI-1 levels generally are unable to distinguish
between the different forms of uPA and PAI-1; thus, the
overall ELISA signal results from a mixture of substances
(e.g., pro-, active, and complexed forms of the analyte).
Therefore, it has been proposed that the levels of uPA:PAI-
1 complex may provide additional valuable predictive
information. Indeed, it has been demonstrated by Man-
ders et al. that increased uPA:PAI-1 complex levels, like
uPA and PAI-1 levels separately, were significantly associ-
ated with poor overall survival, moreover, the expression
of uPA:PAI-1 complex independently predicted the effi-
cacy of adjuvant chemotherapy in patients with primary
breast cancer [29].
We confirm the previous observations that preoperative
serum CATB [51,53,55], plasma uPA [52] and PAI-1 [54]
concentrations are significantly higher in CRC than those
found in control non-cancer patients. In addition, with
respect to cathepsins, we demonstrated that not only
CATB but also CATL is elevated in sera of CRC patients.
Interestingly, no statistically significant differences were
seen in association with CEA and CA 19-9.
We demonstrate for the first time that antigen levels of
CATB, CATL and PAI-1 were significantly higher in blood
samples from patients with colorectal adenomas com-
pared to the controls. Thus our results with previous
results obtained in colorectal tissues [42,57] confirm that
CATB, CATL and PAI-1 may be involved in the progres-
sion from premalignant colorectal adenoma into CRC.
When proteases, CEA and CA 19-9 were used as single
markers, we found that sensitivity of PAI-1 (94%), CATB
(82%), uPA (69%) and CATL (41%) were more indicative
for CRC than CEA or CA 19-9 (30% and 18%, respec-
tively). Our data are in agreement with observations of
Huber et al. [52]. They have reported that sensitivity of
uPA was superior to that of the established markers
(75.5% vs. 51.5% of both CEA and CA 19-9). Specificity
of CATB and PAI-1 were in the same range than that of CA
19-9 or CEA. PAI-1, CATB and uPA demonstrated a better
accuracy than CEA or CA 19-9, PAI-1 showing the highest
accuracy.
Survival curves stratified by cathepsin B, cathepsin L and plasminogen activator inhibitor type-1 in colorectal cancer Figure 2
Survival curves stratified by cathepsin B, cathepsin L and plasminogen activator inhibitor type-1 in colorectal 
cancer. The association of preoperative serum cathepsin B (CATB), cathepsin L (CATL) and plasma plasminogen activator 
inhibitor type-1 (PAI-1) antigen levels and overall survival in patients with primary colorectal carcinoma (CRC) (n = 56). By 
using the median values of CATB, CATL and PAI-1 the patients were divided into two groups. High antigen levels identified 
patients with shorter survival and those who were at higher risk of death. Group-oriented curves for survival were calculated 
according to the Kaplan-Meier method. The P values are shown in the figure. A. CATB in sera of patients with CRC (CATB 
median as a cut-off value, 8.75 ng/ml). B. CATL in sera of patients with CRC (CATL median as a cut-off value, 1.1 ng/ml). C. 
PAI-1 in plasma of patients with CRC (PAI-1 median as a cut-off value, 52.45 ng/ml).BMC Cancer 2008, 8:194 http://www.biomedcentral.com/1471-2407/8/194
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It has been suggested that a combined use of different
tumor-associated antigens might be of better clinical
value for the detection and follow-up of various cancers.
The simultaneous determination of several markers led to
a greater sensitivity in our group of CRC patients: PAI-1
combined with CATB or UPA was superior compared to
the combination of all other markers, including proteases
with CEA or CA 19-9. In addition, the sensitivity of CEA
or CA 19-9 in combination with a protease antigen level
was more indicative for CRC than CEA or CA 19-9 alone.
Furthermore, during the multiparametric tumor marker
analysis, the combined use of two markers in all combina-
tions led to a further increase in specificity.
This observation was confirmed by the data we obtained
by examining the correlation of the investigated parame-
ters with Dukes staging, an established predictor of prog-
nosis. While CATL and uPA did not show any correlation
with the stage, CATB, PAI-1, CEA and CA 19-9 did show a
significant increase in patients with advanced stage.
Increased pre-operative serum levels of CEA and CA 19-9
have been already shown to correlate with shorter disease
free and overall survival [8-12] It has been also previously
reported that higher serum levels of CATB [51,53,55] and
plasma levels of PAI-1 [54] are correlated with advanced
tumor stage and shorter survival in CRC. According to our
experience, in a univariate survival analysis not only CATB
and PAI-1, but also CATL antigen levels were significant in
prediction of survival. High serum CATB, CATL and
plasma PAI-1 antigen levels indeed identified patients
with shorter survival and those who were at higher risk of
death. In addition, PAI-1 and CATB proved as independ-
ent predictor variables in a multivariate statistical analysis.
With respect to the commonly used tumor markers, only
CA 19-9 correlated significantly with survival and was
found to be independent prognostic factor. In our series
no significant correlation was observed in association
with respect to uPA antigen levels, CEA, tumor grade,
tumor location, age and gender.
The data in the literature and our own on patient's sur-
vival suggest that serum CATB, CATL and plasma PAI-1
levels might be more useful than the traditionally used
tumor markers. Our results are in full agreement with
recent guidelines regarding the use of CEA or CA 19-9 in
CRC. According to these guideline recommendations,
inadequate sensitivity severely limits the value of CEA for
the diagnosis of CRC, therefore CEA should not be used
to screen for early CRC. Further, data are insufficient to
support the use of CEA to determine whether to treat a
patient with adjuvant chemotherapy. On the other hand,
CEA is the marker of choice for monitoring metastatic
CRC during systemic therapy. With respect to CA 19-9,
although preoperative elevated levels may provide prog-
nostic information, present data are insufficient to recom-
mend CA 19-9 for screening, diagnosis, surveillance or
monitoring treatment of patients with CRC [58,59].
We report for the first time that serum CATB antigen levels
significantly correlate with plasma uPA and PAI-1 levels in
CRC, and a significant correlation is also found between
the antigen levels of CATL and PAI-1. This confirms previ-
ous data obtained in gastrointestinal cancerous tissues on
a concomitant activation of these systems [21,24,26,27],
while the simultaneous up-regulation of cysteine and ser-
ine proteases in CRC strongly confirms the role of cathep-
sins and the uPA/PAI-1 system in the biology of CRC.
Conclusion
In summary, our data provide evidence for possible clini-
cal application of the determination of CATB, CATL, uPA
and PAI-1 in addition to CEA and CA 19-9 in identical
blood samples in patients with CRC. At the time of clini-
cal presentation, proteases are more sensitive indicators of
diagnosis than the most commonly used markers CEA
and CA 19-9. Even though the benefits of multiparametric
tumor markers analyses are highly questionable, the levels
of sensitivity and specificity reached in our study seem to
open the door to such an approach in CRC. On the other
hand, we demonstrate the clear-cut prognostic impact of
serum CATB, CATL and plasma PAI-1 antigen levels for
patients with CRC. Moreover, in multivariate analysis,
PAI-1 and CATB were strong and independent prognostic
factors in CRC. Finally, our results suggest that CATB,
CATL and PAI-1 may have a crucial role not only in the
invasive process of cancer, but also in the progression of
colorectal precancerous lesions into cancer.
Abbreviations
AUC: area under curve; CATB: cathepsin B; CATL: cathep-
sin L; CEA: carcinoembryonic antigen; CA 19-9: carbohy-
drate antigen 19-9; 95%CL: 95% confidence limits; ELISA:
enzyme-linked immunoassay; HR: Hazard ratio; PAI-1:
plasminogen activator inhibitor type-1; pro-uPA: pro-
urokinase-type plasminogen activator; ROC: receiver
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coefficient; uPA: urokinase-type plasminogen activator.
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